Experimental integrase inhibitor GSK-572 shows continued promise

aidsmap.com: "The second-generation integrase inhibitor S/GSK1349572, or GSK-572 for short, continues to demonstrate potent antiviral activity – including activity against HIV strains resistant to raltegravir (Isentress) – as it prepares to enter Phase III clinical trials, according to two studies presented this week at the Eighteenth International AIDS Conference in Vienna."